CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Coverage criteria for topical and oral prescription treatments for rosacea

Defines authorization and duration of approval for listed topical and oral prescription products used to treat rosacea (inflammatory lesions and/or persistent facial erythema); applies to pharmacy benefit management determinations for members covered by Neighborhood Health Plan of Rhode Island.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyCoverage criteria for topical and oral prescription treatments for rosacea

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain prior authorization and document a diagnosis of rosacea plus symptom reduction from baseline; initial approvals are typically limited to 4 months with continuation durations dependent on product.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

7products listed

4initial approval (months)

12Emrosi continuation (months)

36Other continuation (months)

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Authorization criteria

Covered when ALL of the following are met.

Authorization for listed rosacea drugs: Patient has a documented diagnosis of rosacea.

Authorization for listed rosacea drugs: Patient has experienced a reduction in rosacea symptoms from baseline (e.g., inflammatory papules or pustules, facial erythema).

Applies to listed topical agents and Emrosi; duration limits apply per product (see DOA).

Emrosi (minocycline extended-release) is not evaluated for the treatment or prevention of infections. To reduce the development of drug-resistant bacteria and to help preserve the effectiveness of other antibacterial agents, Emrosi should be used only as indicated for rosacea and not for prophylaxis or treatment of infectious conditions.

Clinical studies of azelaic acid (Finacea) observed some reduction in erythema when papules and pustules were also present; however, efficacy for treating erythema alone (in the absence of papules and pustules) has not been evaluated. Use of Finacea solely for erythema-only rosacea therefore lacks established evidence of benefit.

Provider Actions and Authorization Rules

Prior Authorization

Prior Authorization Required

Prior authorization is required for the listed products. Initial approvals are limited (typically 4 months); continuation approvals have specified durations depending on product.

Emrosi: Initial therapy DOA: 4 months; Continuation of therapy DOA: 12 months
Finacea, Mirvaso, Noritate, Rhofade, Soolantra: Initial therapy DOA: 4 months; Continuation of therapy DOA: 36 months

Denial Risk

Authorization Contingent on Diagnosis and Clinical Response

Authorization may be granted only when the patient has a documented diagnosis of rosacea and has demonstrated a reduction in rosacea symptoms from baseline (for example, decreased inflammatory papules or pustules, or reduced facial erythema).

Diagnosis of rosacea documented in the medical record
Documented reduction in rosacea symptoms from baseline (e.g., inflammatory papules or pustules, facial erythema)

Documentation Required

Medical Record Documentation Required

Medical records must document the diagnosis of rosacea and evidence of symptom reduction from baseline to support continuation of therapy decisions. Maintain documentation of baseline signs and follow-up assessments used to determine clinical improvement.

Record of rosacea diagnosis (clinical notes, diagnostic code)
Baseline symptom documentation and follow-up assessments demonstrating reduction

Background

Rosacea commonly presents with inflammatory papules and pustules and/or persistent facial erythema. Management includes topical agents and an oral extended-release minocycline formulation; some therapies primarily target inflammatory lesions (papules and pustules) while others target persistent erythema. Authorization decisions for listed rosacea agents require a documented diagnosis of rosacea and evidence of symptom reduction from baseline, and product-specific duration limits apply.

Product Indications

Product indications

Emrosi (minocycline HCl ER)Indicated to treat inflammatory lesions (papules and pustules) of rosacea in adults.

Finacea Gel (azelaic acid 15%)Indicated for topical treatment of the inflammatory papules and pustules of mild to moderate rosacea.

Mirvaso (brimonidine topical gel 0.33%)Indicated for topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years or older.

Noritate (metronidazole topical)Indicated for the topical treatment of inflammatory lesions and erythema of rosacea.

Rhofade (oxymetazoline 1% cream)Indicated for the topical treatment of persistent facial erythema associated with rosacea in adults.

Soolantra (ivermectin cream)Indicated for the treatment of inflammatory lesions of rosacea.